drugset / Trial / NCT00092976

Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery

NCT00092976

Phase 4 Completed 15 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this clinical research study is to evaluate the safety and efficacy of ReFacto in subjects with hemophilia A undergoing major surgery monitored using the chromogenic substrate assay at the local laboratory.

Timeline

Start
2003-02
Primary completion
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Moroctocog alfa Protein / enzyme biologic

Indications